Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Income from Continuing Operations (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Income from Continuing Operations for 13 consecutive years, with 58447000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 1.63% to 58447000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 285042000.0, a 38.82% increase, with the full-year FY2025 number at 285042000.0, up 38.82% from a year prior.
  • Income from Continuing Operations was 58447000.0 for Q4 2025 at Madrigal Pharmaceuticals, up from 111118000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 42239000.0 in Q2 2025 to a low of 151971000.0 in Q2 2024.
  • A 5-year average of 83101650.0 and a median of 75067000.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: crashed 91.87% in 2024, then soared 72.21% in 2025.
  • Madrigal Pharmaceuticals' Income from Continuing Operations stood at 64549000.0 in 2021, then crashed by 33.08% to 85905000.0 in 2022, then crashed by 30.6% to 112194000.0 in 2023, then soared by 47.04% to 59416000.0 in 2024, then increased by 1.63% to 58447000.0 in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Income from Continuing Operations are 58447000.0 (Q4 2025), 111118000.0 (Q3 2025), and 42239000.0 (Q2 2025).